- Home
- REBN vs ENSC Comparison
REBN vs ENSC Comparison
Compare REBN & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- ENSC
- Stock Information
- Founded
- REBN 2015
- ENSC 2003
- Country
- REBN United States
- ENSC United States
- Employees
- REBN N/A
- ENSC N/A
- Industry
- REBN Restaurants
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- ENSC Health Care
- Exchange
- REBN Nasdaq
- ENSC Nasdaq
- Market Cap
- REBN 12.8M
- ENSC 4.9M
- IPO Year
- REBN 2022
- ENSC N/A
- Fundamental
- Price
- REBN $3.10
- ENSC $2.26
- Analyst Decision
- REBN
- ENSC
- Analyst Count
- REBN 0
- ENSC 0
- Target Price
- REBN N/A
- ENSC N/A
- AVG Volume (30 Days)
- REBN 62.3K
- ENSC 62.7K
- Earning Date
- REBN 08-18-2025
- ENSC 08-13-2025
- Dividend Yield
- REBN N/A
- ENSC N/A
- EPS Growth
- REBN N/A
- ENSC N/A
- EPS
- REBN N/A
- ENSC N/A
- Revenue
- REBN $6,103,732.00
- ENSC $6,224,081.00
- Revenue This Year
- REBN $335.98
- ENSC N/A
- Revenue Next Year
- REBN N/A
- ENSC $1,381.48
- P/E Ratio
- REBN N/A
- ENSC N/A
- Revenue Growth
- REBN 3.38
- ENSC 256.35
- 52 Week Low
- REBN $1.03
- ENSC $1.62
- 52 Week High
- REBN $8.30
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- REBN 67.41
- ENSC 50.20
- Support Level
- REBN $2.61
- ENSC $2.09
- Resistance Level
- REBN $2.78
- ENSC $2.40
- Average True Range (ATR)
- REBN 0.18
- ENSC 0.12
- MACD
- REBN 0.07
- ENSC 0.02
- Stochastic Oscillator
- REBN 92.72
- ENSC 59.21
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.